The Claim
In obese mice on a high-fat diet, 8 weeks of empagliflozin treatment increased plasma adiponectin and IL-33 concentrations and decreased plasma IL-6 and MCP-1 concentrations, resulting in a systemic shift toward an anti-inflammatory adipokine profile.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice fed a high-fat diet, a daily dose of empagliflozin for eight weeks raised levels of two anti-inflammatory signaling molecules in the blood and lowered levels of two pro-inflammatory signaling molecules, changing the overall pattern of fat-derived signaling molecules toward a less inflammatory state.
See the scientific wording
In obese mice on a high-fat diet, empagliflozin treatment for 8 weeks increased plasma adiponectin and IL-33 while decreasing IL-6 and MCP-1, indicating a systemic shift toward an anti-inflammatory adipokine profile.
By blocking sugar reabsorption in the kidneys, empagliflozin forces the body to burn more fat for energy, which stresses fat cells and causes them to change into a more active, heat-burning form. This stress also signals immune cells in fat tissue to switch from a pro-inflammatory state to an anti-inflammatory state. These changed immune cells then release proteins that reduce inflammation and increase beneficial fat signals, while suppressing harmful ones.
What the research says
1 studyIn obese mice, a diabetes drug called empagliflozin made their fat tissue release more helpful proteins and fewer harmful ones, which helped reduce inflammation and improve metabolism.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.